Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia, B-cell lymphoma, non-Hodgkin lymphoma and multiple myeloma. Despite reporting high response rates, the use of CAR-T therapy is associated with a number of practical challenges, including treatment-related adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as high costs and manufacturing difficulties. It is thus crucial to reduce the incidence and optimize the management of toxicities through careful patient selection and monitoring. CAR-T therapy is also being explored as a treatment option for chronic lymphocytic leukemia (CLL), where attempts with CAR-T have been unsuccessful due to CLL-induced T-cell dysfunction, a process that is currently not well understood.
In this podcast, Arnon Nagler, MD, MSc, of the Chaim Sheba Medical Center, Tel-Hashomer, Israel, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Barcelona, Spain, Christian Chabannon, MD, PhD, of the Institut Paoli Calmettes, Marseille, France, and Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discuss key considerations for the use of CAR-T therapy in clinical practice, as presented at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH) 2021.
Highlights from iwCLL 2021
IMW 2021: MRD in myeloma
CAR-T vs bispecifics: replacing ASCT in myeloma
EHA 2021: antibody therapies for NHL
EHA 2021: updates on novel agents for AML
Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs
EHA 2021: targeted therapies for ALL
Texas MPN Workshop 2021: updates on interferons for MPNs
EHA 2021: real-world data on myeloma, lymphoma and CLL
Novel BTK inhibitors for NHL
Latest updates on T-cell therapies for non-Hodgkin lymphoma
Novel CD20/CD3 bispecific antibodies in NHL
Latest updates on CAR-T therapy for lymphoma
EHA & ICML 2021: updates in Hodgkin lymphoma
Latest transplant updates from EHA 2021
Key updates on CAR-T therapy for multiple myeloma
The Lymphoma Sessions: highlights from EHA and ICML 2021
The CLL Sessions: highlights from EHA and ICML 2021
EHA 2021: updates on treatment for MDS
iwNHL 2021: immunotherapy and the microenvironment
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive